Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

63.02 +0.54 (+0.86%)

Official Closing Price Updated: 7:00 PM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? ↗

November 02, 2026

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

Via The Motley Fool

Topics Intellectual Property

MarketBeat Week in Review – 10/26 - 10/30 ↗

October 31, 2026

Stocks wavered after the Fed held rates steady and Alphabet's earnings missed on Search revenue, fueling AI bubble concerns despite strong results from Microsoft and resilient earnings elsewhere.

Via MarketBeat

Topics Artificial Intelligence Earnings Economy

5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings call

October 31, 2026

Bristol Myers Squibb’s third quarter results reflected robust growth in its core portfolio, led by strong commercial execution and momentum across newer prod...

Via StockStory

Topics Earnings

Bristol-Myers Squibb (NYSE:BMY) Posts Inline Q3 Revenue and 12% EPS Beat ↗

October 29, 2026

Via Chartmill

Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors ↗

October 26, 2026

Via Chartmill

BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts

October 30, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 6.9% year on yea...

Via StockStory

Bristol Myers Squibb Q3 Earnings Call Highlights ↗

October 29, 2026

Bristol Myers Squibb (NYSE:BMY) raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a...

Via MarketBeat

Topics Earnings

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction ↗

October 29, 2026

Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Eight growth medicines now each exceed $1 billion in annual sales.

Via The Motley Fool

Topics Earnings

Bristol-Myers Squibb’s (NYSE:BMY) Q3 2026 sales top estimates

October 29, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.9% year on year to $13.07 bil...

Via StockStory

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

October 29, 2026

From Bristol Myers Squibb

Via Business Wire

3 Magnificent Dividend Stocks for Risk-Averse Investors ↗

October 28, 2026

Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.

Via The Motley Fool

Bristol-Myers Squibb (BMY) Q3 earnings: what to expect

October 27, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what investors should kno...

Via StockStory

Topics Artificial Intelligence

Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters ↗

October 27, 2026

The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.

Via The Motley Fool

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation ↗

October 26, 2026

Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.

Via The Motley Fool

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock ↗

October 26, 2026

Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.

Via MarketBeat

Topics Intellectual Property

Bristol Myers Squibb: Bargain Buy or Value Trap? ↗

October 26, 2026

The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.

Via The Motley Fool

Topics Intellectual Property

3 High-Yield Stocks to Buy With $1,000 Right Now ↗

October 26, 2026

These stocks pay yields far above the S&P 500's. And they keep raising their dividends.

Via The Motley Fool

Topics Intellectual Property Stocks

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

October 26, 2026

From Bristol Myers Squibb

Via Business Wire

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? ↗

October 25, 2026

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

October 23, 2026

From Bristol Myers Squibb

Via Business Wire

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

October 23, 2026

From Pathos AI

Via Business Wire

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

October 23, 2026

From Bristol Myers Squibb

Via Business Wire

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? ↗

October 23, 2026

One of these pharma stocks offers more income, but the other offers a safer dividend.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue ↗

October 22, 2026

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Via The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility ↗

October 22, 2026

Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.

Via The Motley Fool

Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results? ↗

October 22, 2026

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

Via The Motley Fool

Topics Artificial Intelligence Lawsuit

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗

October 21, 2026

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Via The Motley Fool

Topics Intellectual Property

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Via The Motley Fool

S&P 500 Top Movers: Gainers and Losers From Today's US Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.